Thoracic Oncology Program, Ste 4th Floor
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Thoracic Oncology Program, Ste 4th FloorSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Frederick Wilson, MD, PhD
Medical Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Board Certified in
Internal Medicine and Medical Oncology
Biography
Frederick Wilson, MD, PhD, is a medical oncologist who cares for patients with lung cancer.
“I enjoy working with patients to understand their treatment goals, to answer their questions and provide guidance at a challenging time, and to help develop treatment plans based on the specific characteristics of their cancer,” he says.
As a member of the Smilow Cancer Hospital Thoracic Oncology Program, Dr. Wilson works alongside colleagues from multiple disciplines, including thoracic surgery, pathology, pulmonology, radiation oncology, and social work, to provide comprehensive care tailored to each patient’s needs.
Dr. Wilson conducts laboratory-based research with a focus on identifying and characterizing new potential targets in lung and other cancers and to understand how cancers become resistant to targeted lung cancer therapies.
Titles
- Assistant Professor
Education & Training
- MDHarvard Medical School (2007)
- PhDYale University (2002)
Additional Information
Publications
- Lenchner D, Petrova Z, Hunihan L, Ashtekar K, Walther Z, Wilson F. A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition. Npj Precision Oncology 2024, 8: 3. PMID: 38182677, PMCID: PMC10770066, DOI: 10.1038/s41698-023-00490-w.
- Gettinger S, Wilson F, Goldberg S, Chiang A, Henick B, Rowen E, Gerrish H, Duffield E, Davies M, Dest V, Komlo A, Pope J, Cheng W, Schalper K, Herbst R. Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition. Journal Of Clinical Oncology 2023, 41: 9121-9121. DOI: 10.1200/jco.2023.41.16_suppl.9121.
- Chiang A, Asghari H, Ashley K, Gettinger S, Goldberg S, Herbst R, Wilson F, Newton B, Cohenuram M, Sabbath K, Talsania A, Russo A, Schultz E, Skrzypczak S, Kingsford C, Schalper K. Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer. Journal Of Clinical Oncology 2023, 41: 8597-8597. DOI: 10.1200/jco.2023.41.16_suppl.8597.
- Chiang A, Austin M, Stewart T, Arammash M, Bhatt S, Gettinger S, Goldberg S, Wilson F, Newton B, Cohenuram M, Sabbath K, Talsania A, Russo A, Herbst R, Schalper K. A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy. Journal Of Clinical Oncology 2022, 40: 8583-8583. DOI: 10.1200/jco.2022.40.16_suppl.8583.
- Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, , Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR Cancer 2022, 8: e33859. PMID: 35588361, PMCID: PMC9164098, DOI: 10.2196/33859.
- Hunihan L, Zhao D, Lazowski H, Li M, Qian Y, Abriola L, Surovtseva YV, Muthusamy V, Tanoue LT, Rothberg B, Schalper KA, Herbst RS, Wilson FH. RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition. Clinical Cancer Research 2022, 28: 3091-3103. PMID: 35247929, PMCID: PMC9288503, DOI: 10.1158/1078-0432.ccr-21-4291.
- Barlesi F, Spira A, Wilson F, Shapiro G, Dooms C, Curioni-Fontecedro A, Esaki T, Cocks K, Trigg A, Stevinson K, Matsuda T, Tran Q, Gray J. Résultats rapportés par les patients (PRO, patient-reported outcomes) de l’étude de phase II CodeBreaK 100 évaluant l’intérêt du sotorasib dans le traitement du cancer du poumon non à petites cellules (CPNPC) avec mutation KRAS p.G12C. Revue Des Maladies Respiratoires Actualités 2022, 14: 207. DOI: 10.1016/j.rmra.2021.11.364.
- Ramalingam S, Skoulidis F, Govindan R, Velcheti V, Li B, Besse B, Dy G, Kim D, Schuler M, Vincent M, Wilson F, Park J, Gutierrez J, Tran Q, Jones S, Wolf J. P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100. Journal Of Thoracic Oncology 2021, 16: s1123. DOI: 10.1016/j.jtho.2021.08.547.
- Talsania A, Zhang J, Wilson F. Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance. 2021, 65-73. DOI: 10.1007/978-3-030-74028-3_4.
- Spira A, Wilson F, Shapiro G, Dooms C, Curioni-Fontecedro A, Esaki T, Barlesi F, Cocks K, Trigg A, Stevinson K, Matsuda T, Tran Q, Gray J. Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2021, 39: 9057-9057. DOI: 10.1200/jco.2021.39.15_suppl.9057.
- Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/s1470-2045(20)30111-x.
- Heist R, Gounder M, Postel-Vinay S, Wilson F, Garralda E, Do K, Shapiro G, Martin-Romano P, Wulf G, Cooper M, Almon C, Nabhan S, Iyer V, Zhang Y, Marks K, Aguado-Fraile E, Basile F, Flaherty K, Burris H. Abstract PR03: A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion. Molecular Cancer Therapeutics 2019, 18: pr03-pr03. DOI: 10.1158/1535-7163.targ-19-pr03.
- Kalra M, McCann K, Karuturi M, Alvarez J, Parkes A, Wesolowski R, Wei M, Mougalian S, Durm G, Qin A, Trivedi M, Armaghani A, Wilson F, Iams W, Cecchini M, Turk A, Soliman H, Tripathy D, Housri S, Housri N. Implementation and uptake of an interactive virtual online tumor board across NCI-Cancer Centers. Journal Of Clinical Oncology 2019, 37: 272-272. DOI: 10.1200/jco.2019.37.27_suppl.272.
- Wilson FH, Herbst RS. Larotrectinib in NTRK-Rearranged Solid Tumors. Biochemistry 2019, 58: 1555-1557. PMID: 30865435, PMCID: PMC7356829, DOI: 10.1021/acs.biochem.9b00126.
- Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova E, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne P. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research 2018, 24: 5963-5976. PMID: 30072474, PMCID: PMC6279568, DOI: 10.1158/1078-0432.ccr-18-0876.
- Stewart T, Finberg K, Walther Z, Sklar JL, Hafez N, Eder JP, Anderson K, Wilson F, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: one tumour, multiple targets. The Lancet Oncology 2018, 19: 1567-1568. PMID: 32956641, DOI: 10.1016/s1470-2045(18)30759-9.
- Wilson FH, Politi K. ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation. Cancer Discovery 2018, 8: 676-678. PMID: 29858224, PMCID: PMC6330656, DOI: 10.1158/2159-8290.cd-18-0368.
- Awad M, Bahcall M, Sholl L, Wilson F, Paweletz C, Capelletti M, Leonardi G, Watanabe M, Baba H, Chambers E, Redig A, Nishino M, VanderLaan P, Costa D, Imamura Y, Janne P. Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2018, 36: 9069-9069. DOI: 10.1200/jco.2018.36.15_suppl.9069.
- Ghazani AA, Oliver NM, St. Pierre JP, Garofalo A, Rainville IR, Hiller E, Treacy DJ, Rojas-Rudilla V, Wood S, Bair E, Parello M, Huang F, Giannakis M, Wilson FH, Stover EH, Corsello SM, Nguyen T, Rana HQ, Church AJ, Lowenstein C, Cibulskis C, Amin-Mansour A, Heng J, Brais L, Santos A, Bauer P, Waldron A, Lo P, Gorman M, Lydon CA, Welch M, McNamara P, Gabriel S, Sholl LM, Lindeman NI, Garber JE, Joffe S, Van Allen EM, Gray SW, Jänne P, Garraway LA, Wagle N. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genetics In Medicine 2017, 19: 787-795. PMID: 28125075, DOI: 10.1038/gim.2016.191.
- Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, Vazquez F, Weir BA, Fitzgerald ME, Tanaka M, Bielski CM, Scott JM, Dennis C, Cowley GS, Boehm JS, Root DE, Golub TR, Clish CB, Bradner JE, Hahn WC, Garraway LA. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 2016, 351: 1214-1218. PMID: 26912360, PMCID: PMC4997612, DOI: 10.1126/science.aad5214.
- Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, Hahn WC, Engelman JA, Meyerson M, Root DE, Jänne PA, Garraway LA. A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer. Cancer Cell 2015, 27: 397-408. PMID: 25759024, PMCID: PMC4398996, DOI: 10.1016/j.ccell.2015.02.005.
- Sharifnia T, Rusu V, Piccioni F, Bagul M, Imielinski M, Cherniack AD, Pedamallu CS, Wong B, Wilson FH, Garraway LA, Altshuler D, Golub TR, Root DE, Subramanian A, Meyerson M. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2014, 111: 18661-18666. PMID: 25512530, PMCID: PMC4284598, DOI: 10.1073/pnas.1412228112.
- Colpo A, Wilson FH, Nardi V, Hochberg E. Administration of Vincristine in a Patient with Machado-Joseph Disease. Oncology 2012, 82: 165-167. PMID: 22433430, PMCID: PMC3701890, DOI: 10.1159/000336602.
- Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, Wilson FH, Currie T, Khanna-Gupta A, Berliner N, Kutok JL, Ebert BL. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2010, 117: 2567-2576. PMID: 21068437, PMCID: PMC3062351, DOI: 10.1182/blood-2010-07-295238.
- Kahle K, Wilson F, Lifton R. Chapter 19 The Syndrome of Hypertension and Hyperkalemia (Pseudohypoaldosteronism Type II) WNK Kinases Regulate the Balance Between Renal Salt Reabsorption and Potassium Secretion. 2009, 313-329. DOI: 10.1016/b978-0-12-449851-8.00019-x.
- Ring A, Kahle K, Cheng S, Leng Q, Lalioti M, Wilson F, Rinehart J, Hebert S, Lifton R. A mutation in WNK4 that causes human hypertension activates the epithelial Na+ channel in vivo. The FASEB Journal 2007, 21: a876-a876. DOI: 10.1096/fasebj.21.6.a876-c.
- Ring AM, Leng Q, Rinehart J, Wilson FH, Kahle KT, Hebert SC, Lifton RP. An SGK1 site in WNK4 regulates Na+ channel and K+ channel activity and has implications for aldosterone signaling and K+ homeostasis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2007, 104: 4025-4029. PMID: 17360471, PMCID: PMC1803763, DOI: 10.1073/pnas.0611728104.
- Ring AM, Cheng SX, Leng Q, Kahle KT, Rinehart J, Lalioti MD, Volkman HM, Wilson FH, Hebert SC, Lifton RP. WNK4 regulates activity of the epithelial Na+ channel in vitro and in vivo. Proceedings Of The National Academy Of Sciences Of The United States Of America 2007, 104: 4020-4024. PMID: 17360470, PMCID: PMC1805455, DOI: 10.1073/pnas.0611727104.
- Leng Q, Kahle KT, Rinehart J, MacGregor GG, Wilson FH, Canessa CM, Lifton RP, Hebert SC. WNK3, a kinase related to genes mutated in hereditary hypertension with hyperkalaemia, regulates the K+ channel ROMK1 (Kir1.1). The Journal Of Physiology 2006, 571: 275-286. PMID: 16357011, PMCID: PMC1796803, DOI: 10.1113/jphysiol.2005.102202.
- Rinehart J, Kahle KT, de los Heros P, Vazquez N, Meade P, Wilson FH, Hebert SC, Gimenez I, Gamba G, Lifton RP. WNK3 kinase is a positive regulator of NKCC2 and NCC, renal cation-Cl- cotransporters required for normal blood pressure homeostasis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2005, 102: 16777-16782. PMID: 16275913, PMCID: PMC1283841, DOI: 10.1073/pnas.0508303102.
- Kahle KT, Wilson FH, Lifton RP. Regulation of diverse ion transport pathways by WNK4 kinase: a novel molecular switch. Trends In Endocrinology And Metabolism 2005, 16: 98-103. PMID: 15808806, DOI: 10.1016/j.tem.2005.02.012.
- Wilson FH, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, Nelson-Williams C, Raja KM, Kashgarian M, Shulman GI, Scheinman SJ, Lifton RP. A Cluster of Metabolic Defects Caused by Mutation in a Mitochondrial tRNA. Science 2004, 306: 1190-1194. PMID: 15498972, PMCID: PMC3033655, DOI: 10.1126/science.1102521.
- Kahle KT, MacGregor GG, Wilson FH, Van Hoek AN, Brown D, Ardito T, Kashgarian M, Giebisch G, Hebert SC, Boulpaep EL, Lifton RP. Paracellular Cl- permeability is regulated by WNK4 kinase: Insight into normal physiology and hypertension. Proceedings Of The National Academy Of Sciences Of The United States Of America 2004, 101: 14877-14882. PMID: 15465913, PMCID: PMC522037, DOI: 10.1073/pnas.0406172101.
- Kahle KT, Wilson FH, Lalioti M, Toka H, Qin H, Lifton RP. WNK kinases: molecular regulators of integrated epithelial ion transport. Current Opinion In Nephrology & Hypertension 2004, 13: 557-562. PMID: 15300163, DOI: 10.1097/00041552-200409000-00012.
- Kahle KT, Gimenez I, Hassan H, Wilson FH, Wong RD, Forbush B, Aronson PS, Lifton RP. WNK4 regulates apical and basolateral Cl– flux in extrarenal epithelia. Proceedings Of The National Academy Of Sciences Of The United States Of America 2004, 101: 2064-2069. PMID: 14769928, PMCID: PMC357052, DOI: 10.1073/pnas.0308434100.
- Kahle KT, Wilson FH, Leng Q, Lalioti MD, O'Connell AD, Dong K, Rapson AK, MacGregor GG, Giebisch G, Hebert SC, Lifton RP. WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion. Nature Genetics 2003, 35: 372-376. PMID: 14608358, DOI: 10.1038/ng1271.
- Choate KA, Kahle KT, Wilson FH, Nelson-Williams C, Lifton RP. WNK1, a kinase mutated in inherited hypertension with hyperkalemia, localizes to diverse Cl−-transporting epithelia. Proceedings Of The National Academy Of Sciences Of The United States Of America 2003, 100: 663-668. PMID: 12522152, PMCID: PMC141053, DOI: 10.1073/pnas.242728499.
- Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, Lifton RP. Molecular pathogenesis of inherited hypertension with hyperkalemia: The Na–Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proceedings Of The National Academy Of Sciences Of The United States Of America 2003, 100: 680-684. PMID: 12515852, PMCID: PMC141056, DOI: 10.1073/pnas.242735399.
- Lifton RP, Wilson FH, Choate KA, Geller DS. Salt and blood pressure: new insight from human genetic studies. Cold Spring Harbor Symposia On Quantitative Biology 2002, 67: 445-50. PMID: 12858570, DOI: 10.1101/sqb.2002.67.445.
- Wilson F, Disse-Nicodème S, Choate K, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford D, Lipkin G, Achard J, Feely M, Dussol B, Berland Y, Unwin R, Mayan H, Simon D, Farfel Z, Jeunemaitre X, Lifton R. Human Hypertension Caused by Mutations in WNK Kinases. Science 2001, 293: 1107-1112. PMID: 11498583, DOI: 10.1126/science.1062844.
- Race J, Makhlouf F, Logue P, Wilson F, Dunham P, Holtzman E. Molecular cloning and functional characterization of KCC3, a new K-Cl cotransporter. American Journal Of Physiology 1999, 277: c1210-c1219. PMID: 10600773, DOI: 10.1152/ajpcell.1999.277.6.c1210.
Departments and Programs
Locations
Thoracic Oncology Program, Ste 4th Floor
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Thoracic Oncology Program, Ste 4th FloorSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Biography
Frederick Wilson, MD, PhD, is a medical oncologist who cares for patients with lung cancer.
“I enjoy working with patients to understand their treatment goals, to answer their questions and provide guidance at a challenging time, and to help develop treatment plans based on the specific characteristics of their cancer,” he says.
As a member of the Smilow Cancer Hospital Thoracic Oncology Program, Dr. Wilson works alongside colleagues from multiple disciplines, including thoracic surgery, pathology, pulmonology, radiation oncology, and social work, to provide comprehensive care tailored to each patient’s needs.
Dr. Wilson conducts laboratory-based research with a focus on identifying and characterizing new potential targets in lung and other cancers and to understand how cancers become resistant to targeted lung cancer therapies.
Titles
- Assistant Professor
Education & Training
- MDHarvard Medical School (2007)
- PhDYale University (2002)
Additional Information
Publications
- Lenchner D, Petrova Z, Hunihan L, Ashtekar K, Walther Z, Wilson F. A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition. Npj Precision Oncology 2024, 8: 3. PMID: 38182677, PMCID: PMC10770066, DOI: 10.1038/s41698-023-00490-w.
- Gettinger S, Wilson F, Goldberg S, Chiang A, Henick B, Rowen E, Gerrish H, Duffield E, Davies M, Dest V, Komlo A, Pope J, Cheng W, Schalper K, Herbst R. Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition. Journal Of Clinical Oncology 2023, 41: 9121-9121. DOI: 10.1200/jco.2023.41.16_suppl.9121.
- Chiang A, Asghari H, Ashley K, Gettinger S, Goldberg S, Herbst R, Wilson F, Newton B, Cohenuram M, Sabbath K, Talsania A, Russo A, Schultz E, Skrzypczak S, Kingsford C, Schalper K. Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer. Journal Of Clinical Oncology 2023, 41: 8597-8597. DOI: 10.1200/jco.2023.41.16_suppl.8597.
- Chiang A, Austin M, Stewart T, Arammash M, Bhatt S, Gettinger S, Goldberg S, Wilson F, Newton B, Cohenuram M, Sabbath K, Talsania A, Russo A, Herbst R, Schalper K. A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy. Journal Of Clinical Oncology 2022, 40: 8583-8583. DOI: 10.1200/jco.2022.40.16_suppl.8583.
- Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, , Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR Cancer 2022, 8: e33859. PMID: 35588361, PMCID: PMC9164098, DOI: 10.2196/33859.
- Hunihan L, Zhao D, Lazowski H, Li M, Qian Y, Abriola L, Surovtseva YV, Muthusamy V, Tanoue LT, Rothberg B, Schalper KA, Herbst RS, Wilson FH. RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition. Clinical Cancer Research 2022, 28: 3091-3103. PMID: 35247929, PMCID: PMC9288503, DOI: 10.1158/1078-0432.ccr-21-4291.
- Barlesi F, Spira A, Wilson F, Shapiro G, Dooms C, Curioni-Fontecedro A, Esaki T, Cocks K, Trigg A, Stevinson K, Matsuda T, Tran Q, Gray J. Résultats rapportés par les patients (PRO, patient-reported outcomes) de l’étude de phase II CodeBreaK 100 évaluant l’intérêt du sotorasib dans le traitement du cancer du poumon non à petites cellules (CPNPC) avec mutation KRAS p.G12C. Revue Des Maladies Respiratoires Actualités 2022, 14: 207. DOI: 10.1016/j.rmra.2021.11.364.
- Ramalingam S, Skoulidis F, Govindan R, Velcheti V, Li B, Besse B, Dy G, Kim D, Schuler M, Vincent M, Wilson F, Park J, Gutierrez J, Tran Q, Jones S, Wolf J. P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100. Journal Of Thoracic Oncology 2021, 16: s1123. DOI: 10.1016/j.jtho.2021.08.547.
- Talsania A, Zhang J, Wilson F. Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance. 2021, 65-73. DOI: 10.1007/978-3-030-74028-3_4.
- Spira A, Wilson F, Shapiro G, Dooms C, Curioni-Fontecedro A, Esaki T, Barlesi F, Cocks K, Trigg A, Stevinson K, Matsuda T, Tran Q, Gray J. Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2021, 39: 9057-9057. DOI: 10.1200/jco.2021.39.15_suppl.9057.
- Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/s1470-2045(20)30111-x.
- Heist R, Gounder M, Postel-Vinay S, Wilson F, Garralda E, Do K, Shapiro G, Martin-Romano P, Wulf G, Cooper M, Almon C, Nabhan S, Iyer V, Zhang Y, Marks K, Aguado-Fraile E, Basile F, Flaherty K, Burris H. Abstract PR03: A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion. Molecular Cancer Therapeutics 2019, 18: pr03-pr03. DOI: 10.1158/1535-7163.targ-19-pr03.
- Kalra M, McCann K, Karuturi M, Alvarez J, Parkes A, Wesolowski R, Wei M, Mougalian S, Durm G, Qin A, Trivedi M, Armaghani A, Wilson F, Iams W, Cecchini M, Turk A, Soliman H, Tripathy D, Housri S, Housri N. Implementation and uptake of an interactive virtual online tumor board across NCI-Cancer Centers. Journal Of Clinical Oncology 2019, 37: 272-272. DOI: 10.1200/jco.2019.37.27_suppl.272.
- Wilson FH, Herbst RS. Larotrectinib in NTRK-Rearranged Solid Tumors. Biochemistry 2019, 58: 1555-1557. PMID: 30865435, PMCID: PMC7356829, DOI: 10.1021/acs.biochem.9b00126.
- Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova E, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne P. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research 2018, 24: 5963-5976. PMID: 30072474, PMCID: PMC6279568, DOI: 10.1158/1078-0432.ccr-18-0876.
- Stewart T, Finberg K, Walther Z, Sklar JL, Hafez N, Eder JP, Anderson K, Wilson F, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: one tumour, multiple targets. The Lancet Oncology 2018, 19: 1567-1568. PMID: 32956641, DOI: 10.1016/s1470-2045(18)30759-9.
- Wilson FH, Politi K. ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation. Cancer Discovery 2018, 8: 676-678. PMID: 29858224, PMCID: PMC6330656, DOI: 10.1158/2159-8290.cd-18-0368.
- Awad M, Bahcall M, Sholl L, Wilson F, Paweletz C, Capelletti M, Leonardi G, Watanabe M, Baba H, Chambers E, Redig A, Nishino M, VanderLaan P, Costa D, Imamura Y, Janne P. Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2018, 36: 9069-9069. DOI: 10.1200/jco.2018.36.15_suppl.9069.
- Ghazani AA, Oliver NM, St. Pierre JP, Garofalo A, Rainville IR, Hiller E, Treacy DJ, Rojas-Rudilla V, Wood S, Bair E, Parello M, Huang F, Giannakis M, Wilson FH, Stover EH, Corsello SM, Nguyen T, Rana HQ, Church AJ, Lowenstein C, Cibulskis C, Amin-Mansour A, Heng J, Brais L, Santos A, Bauer P, Waldron A, Lo P, Gorman M, Lydon CA, Welch M, McNamara P, Gabriel S, Sholl LM, Lindeman NI, Garber JE, Joffe S, Van Allen EM, Gray SW, Jänne P, Garraway LA, Wagle N. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genetics In Medicine 2017, 19: 787-795. PMID: 28125075, DOI: 10.1038/gim.2016.191.
- Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, Vazquez F, Weir BA, Fitzgerald ME, Tanaka M, Bielski CM, Scott JM, Dennis C, Cowley GS, Boehm JS, Root DE, Golub TR, Clish CB, Bradner JE, Hahn WC, Garraway LA. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 2016, 351: 1214-1218. PMID: 26912360, PMCID: PMC4997612, DOI: 10.1126/science.aad5214.
- Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, Hahn WC, Engelman JA, Meyerson M, Root DE, Jänne PA, Garraway LA. A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer. Cancer Cell 2015, 27: 397-408. PMID: 25759024, PMCID: PMC4398996, DOI: 10.1016/j.ccell.2015.02.005.
- Sharifnia T, Rusu V, Piccioni F, Bagul M, Imielinski M, Cherniack AD, Pedamallu CS, Wong B, Wilson FH, Garraway LA, Altshuler D, Golub TR, Root DE, Subramanian A, Meyerson M. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2014, 111: 18661-18666. PMID: 25512530, PMCID: PMC4284598, DOI: 10.1073/pnas.1412228112.
- Colpo A, Wilson FH, Nardi V, Hochberg E. Administration of Vincristine in a Patient with Machado-Joseph Disease. Oncology 2012, 82: 165-167. PMID: 22433430, PMCID: PMC3701890, DOI: 10.1159/000336602.
- Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, Wilson FH, Currie T, Khanna-Gupta A, Berliner N, Kutok JL, Ebert BL. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2010, 117: 2567-2576. PMID: 21068437, PMCID: PMC3062351, DOI: 10.1182/blood-2010-07-295238.
- Kahle K, Wilson F, Lifton R. Chapter 19 The Syndrome of Hypertension and Hyperkalemia (Pseudohypoaldosteronism Type II) WNK Kinases Regulate the Balance Between Renal Salt Reabsorption and Potassium Secretion. 2009, 313-329. DOI: 10.1016/b978-0-12-449851-8.00019-x.
- Ring A, Kahle K, Cheng S, Leng Q, Lalioti M, Wilson F, Rinehart J, Hebert S, Lifton R. A mutation in WNK4 that causes human hypertension activates the epithelial Na+ channel in vivo. The FASEB Journal 2007, 21: a876-a876. DOI: 10.1096/fasebj.21.6.a876-c.
- Ring AM, Leng Q, Rinehart J, Wilson FH, Kahle KT, Hebert SC, Lifton RP. An SGK1 site in WNK4 regulates Na+ channel and K+ channel activity and has implications for aldosterone signaling and K+ homeostasis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2007, 104: 4025-4029. PMID: 17360471, PMCID: PMC1803763, DOI: 10.1073/pnas.0611728104.
- Ring AM, Cheng SX, Leng Q, Kahle KT, Rinehart J, Lalioti MD, Volkman HM, Wilson FH, Hebert SC, Lifton RP. WNK4 regulates activity of the epithelial Na+ channel in vitro and in vivo. Proceedings Of The National Academy Of Sciences Of The United States Of America 2007, 104: 4020-4024. PMID: 17360470, PMCID: PMC1805455, DOI: 10.1073/pnas.0611727104.
- Leng Q, Kahle KT, Rinehart J, MacGregor GG, Wilson FH, Canessa CM, Lifton RP, Hebert SC. WNK3, a kinase related to genes mutated in hereditary hypertension with hyperkalaemia, regulates the K+ channel ROMK1 (Kir1.1). The Journal Of Physiology 2006, 571: 275-286. PMID: 16357011, PMCID: PMC1796803, DOI: 10.1113/jphysiol.2005.102202.
- Rinehart J, Kahle KT, de los Heros P, Vazquez N, Meade P, Wilson FH, Hebert SC, Gimenez I, Gamba G, Lifton RP. WNK3 kinase is a positive regulator of NKCC2 and NCC, renal cation-Cl- cotransporters required for normal blood pressure homeostasis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2005, 102: 16777-16782. PMID: 16275913, PMCID: PMC1283841, DOI: 10.1073/pnas.0508303102.
- Kahle KT, Wilson FH, Lifton RP. Regulation of diverse ion transport pathways by WNK4 kinase: a novel molecular switch. Trends In Endocrinology And Metabolism 2005, 16: 98-103. PMID: 15808806, DOI: 10.1016/j.tem.2005.02.012.
- Wilson FH, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, Nelson-Williams C, Raja KM, Kashgarian M, Shulman GI, Scheinman SJ, Lifton RP. A Cluster of Metabolic Defects Caused by Mutation in a Mitochondrial tRNA. Science 2004, 306: 1190-1194. PMID: 15498972, PMCID: PMC3033655, DOI: 10.1126/science.1102521.
- Kahle KT, MacGregor GG, Wilson FH, Van Hoek AN, Brown D, Ardito T, Kashgarian M, Giebisch G, Hebert SC, Boulpaep EL, Lifton RP. Paracellular Cl- permeability is regulated by WNK4 kinase: Insight into normal physiology and hypertension. Proceedings Of The National Academy Of Sciences Of The United States Of America 2004, 101: 14877-14882. PMID: 15465913, PMCID: PMC522037, DOI: 10.1073/pnas.0406172101.
- Kahle KT, Wilson FH, Lalioti M, Toka H, Qin H, Lifton RP. WNK kinases: molecular regulators of integrated epithelial ion transport. Current Opinion In Nephrology & Hypertension 2004, 13: 557-562. PMID: 15300163, DOI: 10.1097/00041552-200409000-00012.
- Kahle KT, Gimenez I, Hassan H, Wilson FH, Wong RD, Forbush B, Aronson PS, Lifton RP. WNK4 regulates apical and basolateral Cl– flux in extrarenal epithelia. Proceedings Of The National Academy Of Sciences Of The United States Of America 2004, 101: 2064-2069. PMID: 14769928, PMCID: PMC357052, DOI: 10.1073/pnas.0308434100.
- Kahle KT, Wilson FH, Leng Q, Lalioti MD, O'Connell AD, Dong K, Rapson AK, MacGregor GG, Giebisch G, Hebert SC, Lifton RP. WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion. Nature Genetics 2003, 35: 372-376. PMID: 14608358, DOI: 10.1038/ng1271.
- Choate KA, Kahle KT, Wilson FH, Nelson-Williams C, Lifton RP. WNK1, a kinase mutated in inherited hypertension with hyperkalemia, localizes to diverse Cl−-transporting epithelia. Proceedings Of The National Academy Of Sciences Of The United States Of America 2003, 100: 663-668. PMID: 12522152, PMCID: PMC141053, DOI: 10.1073/pnas.242728499.
- Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, Lifton RP. Molecular pathogenesis of inherited hypertension with hyperkalemia: The Na–Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proceedings Of The National Academy Of Sciences Of The United States Of America 2003, 100: 680-684. PMID: 12515852, PMCID: PMC141056, DOI: 10.1073/pnas.242735399.
- Lifton RP, Wilson FH, Choate KA, Geller DS. Salt and blood pressure: new insight from human genetic studies. Cold Spring Harbor Symposia On Quantitative Biology 2002, 67: 445-50. PMID: 12858570, DOI: 10.1101/sqb.2002.67.445.
- Wilson F, Disse-Nicodème S, Choate K, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford D, Lipkin G, Achard J, Feely M, Dussol B, Berland Y, Unwin R, Mayan H, Simon D, Farfel Z, Jeunemaitre X, Lifton R. Human Hypertension Caused by Mutations in WNK Kinases. Science 2001, 293: 1107-1112. PMID: 11498583, DOI: 10.1126/science.1062844.
- Race J, Makhlouf F, Logue P, Wilson F, Dunham P, Holtzman E. Molecular cloning and functional characterization of KCC3, a new K-Cl cotransporter. American Journal Of Physiology 1999, 277: c1210-c1219. PMID: 10600773, DOI: 10.1152/ajpcell.1999.277.6.c1210.
Departments and Programs
Locations
Thoracic Oncology Program, Ste 4th Floor
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Thoracic Oncology Program, Ste 4th FloorSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Thoracic Oncology Program, Ste 4th Floor
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Thoracic Oncology Program, Ste 4th FloorSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511